JPMorgan Chase & Co. Initiates Coverage on Electra Therapeutics (NASDAQ:ETRA)

Key Points

• JPMorgan initiated coverage of Electra Therapeutics with an “overweight” rating and a $36 price target, implying nearly 298% upside from the reported $9.05 share price.
• Analyst sentiment is broadly positive: Electra has a consensus “Buy” rating and an average price target of $34.67, based on one Strong Buy, four Buys, and one Hold.
• Company directors reported significant insider purchases, with Carl Gordon and OrbiMed Advisors each acquiring 1.33 million shares at $15 per share, while Electra continues developing immune-cell modulation therapies for cancer and autoimmune diseases.

Equities researchers at JPMorgan Chase & Co. initiated coverage on shares of Electra Therapeutics (NASDAQ:ETRA - Get Free Report) in a report released on Thursday, Briefing.com reports. The firm set an "overweight" rating and a $36.00 price target on the stock. JPMorgan Chase & Co.'s target price suggests a potential upside of 297.79% from the company's current price.

ETRA has been the subject of several other research reports. Cantor Fitzgerald began coverage on shares of Electra Therapeutics in a research report on Tuesday, October 13th. They issued an "overweight" rating for the company. Wall Street Zen upgraded Electra Therapeutics to a "hold" rating in a research report on Saturday, September 26th. Evercore assumed coverage on shares of Electra Therapeutics in a research note on Tuesday, October 13th. They set an "outperform" rating and a $36.00 target price for the company. TD Cowen began coverage on shares of Electra Therapeutics in a report on Tuesday, October 13th. They issued a "buy" rating for the company. Finally, Jefferies Financial Group began coverage on Electra Therapeutics in a report on Tuesday, October 13th. They set a "buy" rating and a $32.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $34.67.

Electra Therapeutics Stock Up 2.7%

Shares of NASDAQ ETRA opened at $9.05 on Thursday. Electra Therapeutics has a 1 year low of $8.50 and a 1 year high of $15.50.

Insider Buying and Selling at Electra Therapeutics

In other Electra Therapeutics news, Director Carl Gordon bought 1,333,333 shares of Electra Therapeutics stock in a transaction dated Monday, September 21st. The stock was bought at an average price of $15.00 per share, for a total transaction of $19,999,995.00. Following the completion of the acquisition, the director directly owned 5,126,891 shares of the company's stock, valued at approximately $76,903,365. This trade represents a 35.15% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Orbimed Advisors Llc purchased 1,333,333 shares of the company's stock in a transaction that occurred on Monday, September 21st. The shares were acquired at an average cost of $15.00 per share, for a total transaction of $19,999,995.00. Following the completion of the transaction, the director directly owned 5,126,891 shares of the company's stock, valued at $76,903,365. This trade represents a 35.15% increase in their position. The disclosure for this purchase is available in the SEC filing.

Electra Therapeutics Company Profile

Electra Therapeutics, Inc NASDAQ: ETRA is a clinical-stage biopharmaceutical company focused on developing therapies that modulate the immune system. The company's research is directed toward selectively influencing immune-cell activity to address serious diseases, including cancer and autoimmune conditions.

Electra Therapeutics is advancing a pipeline of investigational medicines based on its immune-cell modulation approach. Its programs are intended to improve the body's ability to recognize, control, or eliminate disease-associated cells while limiting effects on healthy tissue.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.